CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 40 enrolled
Drug / intervention
Tofacitinibdrug
Likely dose
Tofacitinib 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02312882
NCT02312882N/ACompleted
CompareCT.gov

Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Stanford University·interventional·Posted Dec 9, 2014·Updated Nov 6, 2017

In Brief

A clinical study evaluating Tofacitinib for Alopecia Areata and 2 related conditions. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata, Alopecia Totalis, Alopecia Universalis
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 9, 2014
Enrollment StartDec 1, 2014
Primary CompletionAug 1, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.6 years ago

Interventions

Tofacitinibdrug

Tofacitinib 5 mg tablet taken by mouth twice a day.